{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2020"],"data_sharing_plan":["IPD Sharing (as of September 2023): No"],"condition":["Solid Tumor","Colorectal Neoplasms","Advanced Solid Tumor","Ovarian Neoplasms","Lymphoma","Advanced Lymphoma"],"disease":["Solid Tumor","Colorectal Neoplasms","Advanced Solid Tumor","Ovarian Neoplasms","Lymphoma","Advanced Lymphoma"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2356224"],"location":["United States"],"study_start_month":["11"],"keyword":["Pembrolizumab","Advanced Tumor","Microsatellite stable colorectal","STING agonist","Stimulator of interferon genes","B-Cell Lymphomas","Microsatellite instable colorectal"],"repository":["ECRIN MDR"],"study_status":["Active, not recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma","description":"This clinical trial is evaluating a drug called SNX281 given by itself and in combination with pembrolizumab in participants with advanced solid tumors and lymphoma. The main goals of this study are to:\n* Find the recommended dose of SNX281 that can be given to participants safely alone and in combination with pembrolizumab.\n* Learn more about the side effects and safety profile of SNX281 alone and in combination with pembrolizumab\n* Learn more about pharmacological characteristics of SNX281 alone and in combination with pembrolizumab\n* Learn more about effectiveness of SNX281 alone and in combination with pembrolizumab","dates":{"creation":"2020-11-15"},"accession":"2356224","cross_references":{"ClinicalTrials___gov":["NCT04609579"]}}